登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer
ClinicalTrials.gov 上登记的一项胃癌开放试验,由北京大学人民医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07018063,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
16 岁 至 45 岁;性别:不限
登记记录的入选字段
Histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction (GEJ).
入选标准第 4 条
For gastric body cancer: clinical stage cT3-T4a N+ M0;
入选标准第 5 条
For GEJ cancer: clinical stage cT2-T4a N+ M0;
入选标准第 6 条
Karnofsky performance score ≥70% or ECOG performance status 0-1;
入选标准第 3 条
Hemoglobin ≥90 g/L
入选标准第 13 条
Absolute neutrophil count (ANC) ≥1.5×10⁹/L
入选标准第 14 条
Platelets ≥100×10⁹/L
入选标准第 15 条
ALT and AST ≤2.5× upper limit of normal (ULN)
入选标准第 16 条
Alkaline phosphatase (ALP) ≤2.5× ULN
入选标准第 17 条
Total bilirubin <1.5× ULN
入选标准第 18 条
Serum creatinine <1× ULN
入选标准第 19 条
Patients with HER-2 positive gastric cancer, as determined by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH);
排除标准第 2 条
History of other malignancies within the past 5 years;
排除标准第 6 条
Pregnant or breastfeeding women;
排除标准第 4 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:既往治疗;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07018063,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Participants must meet all of the following inclusion criteria: Male or female, aged ≥16 and ≤45 years; Karnofsky performance score ≥70% or ECOG performance status 0-1; Histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction (GEJ). For gastric body cancer: clinical stage cT3-T4a N+ M0; For GEJ cancer: clinical stage cT2-T4a N+ M0; For cT4b Nany M0 cases: location may be gastric body or GEJ. Staging is based on contrast-enhanced CT, MRI (if needed), and endoscopic ultrasonography (EUS) (if needed); Assessed as resectable after multidisciplinary team (MDT) discussion; Surgical evaluation confirms that D2 radical gastrectomy is feasible; Sufficient physical condition and organ function to tolerate major abdominal surgery; Baseline laboratory tests meet the following criteria: Hemoglobin ≥90 g/L Absolute neutrophil count (ANC) ≥1.5×10⁹/L Platelets ≥100×10⁹/L ALT and AST ≤2.5× upper limit of normal (ULN) Alkaline phosphatase (ALP) ≤2.5× ULN Total bilirubin <1.5× ULN Serum creatinine <1× ULN Serum albumin ≥30 g/L No severe comorbidities that may limit life expectancy to <3 years; Participant is willing and able to comply with the study protocol during the study period; Written informed consent must be signed before screening. Participants must understand their right to withdraw at any time without any loss of benefits; Willing to provide blood and tissue samples.排除标准:Exclusion Criteria:
Participants meeting any of the following criteria will be excluded: Patients with HER-2 positive gastric cancer, as determined by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH); Patients with dMMR (deficient mismatch repair) or MSI-H (microsatellite instability-high) tumors, as determined by IHC; Pregnant or breastfeeding women; Prior treatment for gastric cancer with cytotoxic chemotherapy, radiotherapy, or immunotherapy; History of other malignancies within the past 5 years; Active autoimmune diseases, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, myasthenia gravis; Active inflammatory bowel diseases, such as Crohn's disease or ulcerative colitis; Currently receiving systemic corticosteroids or other immunosuppressive therapy; Prior organ transplantation or use of anti-rejection medications; Active tuberculosis, HIV infection, or severe active hepatitis B or C; History of uncontrolled epilepsy, central nervous system disorders, or psychiatric illnesses that, in the investigator's judgment, may interfere with informed consent or compliance with oral medication; Clinically significant (active) cardiac diseases, including symptomatic coronary artery disease, NYHA class II or above congestive heart failure , severe arrhythmias requiring medical intervention, or myocardial infarction within the past 12 months; Presence of upper gastrointestinal obstruction that may impair the oral intake or absorption of S-1; Severe uncontrolled recurrent infections or other uncontrolled serious comorbidities; Use of any investigational drugs within 4 weeks prior to study enrollment.
引自 ClinicalTrials.gov, NCT07018063, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07018063,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。